Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) PEG Ratio: N/A (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02591 Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
9 GF Score
Price HK$7.60
! 2 Warning Signs
View Full Analysis

What is Guangzhou Innogen Pharmaceutical Group Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Guangzhou Innogen Pharmaceutical Group Co's PE Ratio without NRI is 0.00. Guangzhou Innogen Pharmaceutical Group Co's 5-Year EBITDA growth rate is 0.00%. Therefore, Guangzhou Innogen Pharmaceutical Group Co's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Guangzhou Innogen Pharmaceutical Group Co's PEG Ratio or its related term are showing as below:



HKSE:02591's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Guangzhou Innogen Pharmaceutical Group Co  (HKSE:02591) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Guangzhou Innogen Pharmaceutical Group Co PEG Ratio Related Terms

Guangzhou Innogen Pharmaceutical Group Co PEG Ratio Historical Data

* Premium members only.

The historical data trend for Guangzhou Innogen Pharmaceutical Group Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Innogen Pharmaceutical Group Co PEG Ratio Chart

Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend Dec23 Dec24 Dec25
PEG Ratio
0.00 0.00 0.00

Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio 0.00 0.00 0.00 0.00 0.00

HKSE:02591 vs VRTX, REGN, RVMD: PEG Ratio Comparison

For the Biotechnology subindustry, Guangzhou Innogen Pharmaceutical Group Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guangzhou Innogen Pharmaceutical Group Co PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Guangzhou Innogen Pharmaceutical Group Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Guangzhou Innogen Pharmaceutical Group Co's PEG Ratio falls into.


HKSE:02591
9GF Score
Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Innogen Pharmaceutical Group Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Guangzhou Innogen Pharmaceutical Group Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Guangzhou Innogen Pharmaceutical Group Co Business Description

Address No. 2 Tengfei Second Street, Room 409, Building H Self-numbered Creative Building, China-Singapore Guangzhou Knowledge City, Huangpu District, Guangdong Province, Guangzhou, CHN
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
9GF Score

Get the complete analysis for HKSE:02591

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$7.60
Price